CV Therapeutics’ Ranexa Grows In Fourth Quarter; Partner Talks Continue
This article was originally published in The Pink Sheet Daily
Executive Summary
New heart indication, diabetes could be next, as pendulum swings to company’s favor, analyst tells “The Pink Sheet” DAILY.